VUMC Main Calendar Events

  • 2/13/2019
    12:15 pm - 1:15 pm
    VICB Seminar, Jing Yang, Bristol-Myers Squibb: 'The Discovery of Orally Active Small Molecule PAR4 Antagonists'

      The Vanderbilt Institute of Chemical Biology (VICB) presents Dr. Jing Yang, Bristol-Myers Squibb: "The Discovery of Orally Active Small Molecule PAR4 Antagonists"

    Key Lecture Points:

    The balance between antithrombotic efficacy and bleeding with currently available antiplatelet drugs is suboptimal and many patients remain at high risk of future atherothrombotic events. Thus there is a clear need for newer agents that can provide equivalent or superior antithrombotic efficacy with a lower bleeding profile. Our research is focused on protease-activated receptor 4 (PAR4), a low affinity thrombin receptor, as a promising antiplatelet drug target to provide a potentially safer treatment for
    arterial thrombosis. Below is an outline of our research: 

    · Discovery of first-in-class orally ctive, potent and selective PAR4 antagonists including BMS-986120
    · Preclinical studies of PAR4 antagonist in non-human primate thrombosis and hemostasis models
    · Antithrombotic effect of BMS-986120 in human ex vivo thrombosis chamber study
    · First-in-human tolerability, PKPD and gene
      variant effects of BMS-986120

    Contact: Tia Repscher

Find Us On:
YouTube Twitter Facebook
Share on Google+